WASHINGTON–(BUSINESS WIRE)–The Association for Accessible Medicines (AAM) applauded the U.S. Supreme Court’s decision this week in Sandoz Inc. v. Amgen Inc. that will help speed patient access to biosimilar versions of expensive brand-name biologic medicines. In a unanimous ruling, the Court overturned a lower court decision that had effectively extended …
Tag Archives: The Biosimilars Council
June, 2017
November, 2015
-
4 November
GPhA Says US Biosimilars Reimbursement Rule May Discourage Patient Access
WASHINGTON, DC (October 30, 2015) — The Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA), is disappointed today by the Centers for Medicare & Medicaid Services’ (CMS) decision to group all biosimilars together under one payment calculation and billing code in Medicare Part B, while using a different …